These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23892272)

  • 1. SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity.
    Fang X; Guo L; Jia J; Jin GZ; Zhao B; Zheng YY; Li JQ; Zhang A; Zhen XC
    Acta Pharmacol Sin; 2013 Sep; 34(9):1149-55. PubMed ID: 23892272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.
    Jiang B; Wang F; Yang S; Fang P; Deng ZF; Xiao JL; Hu ZL; Chen JG
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3 beta and a receptor-independent anti-oxidative action.
    Yu Y; Wang JR; Sun PH; Guo Y; Zhang ZJ; Jin GZ; Zhen X
    J Neurochem; 2008 Feb; 104(4):946-56. PubMed ID: 18005341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
    Dutta AK; Ghosh B; Biswas S; Reith ME
    Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
    Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
    PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.
    Han DD; Gu HH
    BMC Pharmacol; 2006 Mar; 6():6. PubMed ID: 16515684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions.
    Perona MT; Waters S; Hall FS; Sora I; Lesch KP; Murphy DL; Caron M; Uhl GR
    Behav Pharmacol; 2008 Sep; 19(5-6):566-74. PubMed ID: 18690111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor.
    Barbier AJ; Aluisio L; Lord B; Qu Y; Wilson SJ; Boggs JD; Bonaventure P; Miller K; Fraser I; Dvorak L; Pudiak C; Dugovic C; Shelton J; Mazur C; Letavic MA; Carruthers NI; Lovenberg TW
    Eur J Pharmacol; 2007 Dec; 576(1-3):43-54. PubMed ID: 17765221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.
    Shao L; Hewitt MC; Malcolm SC; Wang F; Ma J; Campbell UC; Spicer NA; Engel SR; Hardy LW; Jiang ZD; Schreiber R; Spear KL; Varney MA
    J Med Chem; 2011 Aug; 54(15):5283-95. PubMed ID: 21739935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of South African traditional medicine in animal models for depression.
    Pedersen ME; Szewczyk B; Stachowicz K; Wieronska J; Andersen J; Stafford GI; van Staden J; Pilc A; Jäger AK
    J Ethnopharmacol; 2008 Oct; 119(3):542-8. PubMed ID: 18809486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.
    Santra S; Gogoi S; Gopishetty B; Antonio T; Zhen J; Reith ME; Dutta AK
    ChemMedChem; 2012 Dec; 7(12):2093-100. PubMed ID: 23060293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
    Conti MM; Meadows SM; Melikhov-Sosin M; Lindenbach D; Hallmark J; Werner DF; Bishop C
    Neuropharmacology; 2016 Nov; 110(Pt A):125-134. PubMed ID: 27452719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
    Verrico CD; Miller GM; Madras BK
    Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
    Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
    J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SKF83959 is a potent allosteric modulator of sigma-1 receptor.
    Guo L; Zhao J; Jin G; Zhao B; Wang G; Zhang A; Zhen X
    Mol Pharmacol; 2013 Mar; 83(3):577-86. PubMed ID: 23295385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine transporter inhibitory and antiparkinsonian effect of common flowering quince extract.
    Zhao G; Jiang ZH; Zheng XW; Zang SY; Guo LH
    Pharmacol Biochem Behav; 2008 Sep; 90(3):363-71. PubMed ID: 18485464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.
    Santra S; Sharma H; Vedachalam S; Antonio T; Reith M; Dutta A
    Bioorg Med Chem; 2015 Feb; 23(4):821-8. PubMed ID: 25593099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: serotonin, norepinephrine and dopamine reuptake inhibitor.
    Jin ZL; Gao N; Zhou D; Chi MG; Yang XM; Xu JP
    Pharmacol Biochem Behav; 2012 Jan; 100(3):431-9. PubMed ID: 22005599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of D1-like receptor-dependent phosphatidylinositol signal pathway by SKF83959 inhibits voltage-gated sodium channels in cultured striatal neurons.
    Ma J; Long LH; Hu ZL; Zhang H; Han J; Ni L; Wang F; Chen JG; Wu PF
    Brain Res; 2015 Jul; 1615():71-79. PubMed ID: 25912434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative.
    Kolaczynska KE; Thomann J; Hoener MC; Liechti ME
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34361040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.